Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06249750 | Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer | recruiting | Phase 2 | 60 | Pengyuan LiuOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05678270 | A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 70 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06243003 | WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases | recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06246162 | Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06244225 | HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 38 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06240689 | A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood | recruiting | Phase 2 | 104 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06241599 | A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | recruiting | Phase 2 / Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05243212 | Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 75 | Sheba Medical CenterOTHER_GOV | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06190067 | Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma | recruiting | Phase 2 | 40 | Navy General Hospital, BeijingOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06229340 | Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations(NТО-RAS) | recruiting | Phase 2 | 20 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT06220487 | A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL(ABC) | recruiting | Phase 2 | 67 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06220552 | The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma | recruiting | Phase 2 | 20 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06218810 | Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer | recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06211790 | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT05011487 | Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC(NOCE01) | recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06205472 | Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC. | recruiting | Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06196255 | Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05675813 | Genotype-guided Treatment in Newly Diagnosed PTCL(THEORY) | recruiting | Phase 1 / Phase 2 | 264 | Ruijin HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05833763 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.(GOlDiLOX) | recruiting | Phase 2 | 42 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04716686 | Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma | recruiting | Phase 2 | 83 | Shandong UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05964569 | Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma(INDIGO) | recruiting | Phase 2 | 120 | University Hospital HeidelbergOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06190639 | A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC | recruiting | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04894370 | Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma(SPARTANA) | recruiting | Phase 2 | 34 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT06176729 | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients | recruiting | Phase 2 | 30 | Yan Zhang, MDOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06177925 | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | recruiting | Phase 2 | 62 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06173986 | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06155383 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 2 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06170710 | Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC | recruiting | Phase 2 | 173 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06159478 | Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)(Perfume) | recruiting | Phase 2 | 32 | National Cancer Center, JapanOTHER_GOV | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06158269 | DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma | recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05788679 | A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | recruiting | Phase 2 | 200 | Karolinska University HospitalOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04729543 | MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer(MC2TCR) | recruiting | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05694312 | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL | recruiting | Phase 2 | 45 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT04214366 | Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation(ACCO) | recruiting | Phase 2 | 314 | Heidelberg UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06147570 | A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | recruiting | Phase 2 | 62 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT05451784 | Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS(TILS001) | recruiting | Phase 1 / Phase 2 | 20 | Fundacio Clinic BarcelonaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02290145 | Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage | recruiting | Phase 2 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05069857 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | recruiting | Phase 2 | 46 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05961124 | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | recruiting | Phase 2 | 40 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06132711 | Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma(CAR-T) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT05344209 | Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer(LUNGVAC) | recruiting | Phase 2 | 138 | Vestre Viken Hospital TrustOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06125652 | Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06121700 | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G) | recruiting | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06122493 | Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05494060 | XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma(EXPLORING) | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06114225 | Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial(PROMIS) | recruiting | Phase 2 | 43 | Ruijin HospitalOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05849857 | Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries(MERLIN) | recruiting | Phase 2 | 80 | Oslo University HospitalOTHER | 2 | Nov 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 8, 2024source: clinicaltrials